Bioidentical Hormone Therapy. The Molecule Matters.
Same molecular structure as the hormones your body naturally produces. Prescribed as standardized or precision-compounded formulations based on your labs.
Bioidentical vs. Synthetic: What Actually Changes
Not all hormone therapy is the same. The molecule matters, and here is why.
Bioidentical hormones share the exact same molecular structure as the hormones your body makes. Estradiol is estradiol. Progesterone is progesterone. When a bioidentical hormone binds to a receptor, it signals the same way your body’s own hormone would, because it is structurally identical to it. This is the clinical foundation of bioidentical hormone therapy at Tactus Health.
Synthetic hormones work differently. Medroxyprogesterone acetate (MPA), the synthetic progestin used in the original 2002 WHI study, binds to progesterone receptors but also activates glucocorticoid and androgen receptor pathways that natural progesterone does not. Conjugated equine estrogens, also used in the WHI, contain estrogens not naturally present in the human body. Same receptor targets, very different downstream effects, and a measurably different risk profile.
Our medical team uses bioidentical estradiol and micronized progesterone in both standardized (FDA-approved) and precision-compounded formulations. The choice is driven by your labs and your biology, not by a preset hierarchy.
We work exclusively with 503A and 503B FDA-registered compounding pharmacies that provide certificates of analysis for every formulation. We do not work with unregulated compounders or pellet mills that cannot document accuracy and sterility.
Why the Molecule Matters
Same symptom target. Very different receptor behavior. The formulation your provider prescribes determines the risk profile you carry.
Estradiol & Micronized Progesterone
Structurally identical to ovarian hormones. Binds receptors exactly as your body’s own hormones do. The clinical default for all Tactus Health patients.
- No first-pass VTE risk increase via transdermal route
- Micronized progesterone: significantly lower breast cancer signal vs. MPA
- Preserves estradiol’s cardiovascular benefits (MPA partially negates them)
- Progesterone metabolites cross the blood-brain barrier to bind GABA receptors, acting as a natural sleep aid
- FDA-approved formulations widely available and often insurance-covered
CEE & Medroxyprogesterone Acetate
The synthetic hormones studied in the 2002 WHI trial. Different molecular structure, different receptor binding, and a measurably different risk profile.
- Conjugated equine estrogens contain non-human estrogen types
- MPA activates glucocorticoid and androgen receptor pathways
- Higher cardiovascular and breast cancer signals in WHI data
- MPA does not cross blood-brain barrier beneficially
- Not the default at Tactus Health
The WHI Study Did Not Study Bioidentical HRT.
The 2002 Women’s Health Initiative used conjugated equine estrogens and medroxyprogesterone acetate in women averaging 63 years of age, more than a decade past menopause. The findings were real. But they applied to that specific population using those specific synthetic hormones. Transdermal bioidentical estradiol and micronized progesterone were not part of the study. The decades of undertreated women that followed represent one of the most consequential failures of evidence translation in modern medicine.
Two Paths. Same Molecular Standard.
Both FDA-approved and compounded formulations are bioidentical. The difference is not which is better. It is which one matches your biology.
FDA-Approved Formulations
Estradiol patches, gels, sprays, and micronized progesterone capsules. Batch-tested, widely available, and supported by extensive published data. Often covered by insurance.
- Consistent across batches
- Available at standard pharmacies
- Often insurance-covered
- Largest body of published evidence
Custom Formulations
Tailored dosing created by registered compounding pharmacies when your labs call for ratios, combinations, or concentrations that standard products do not offer. Also the only route for low-dose testosterone in women.
- Dosing calibrated to your labs
- Multiple hormones in one delivery
- Low-dose testosterone (no FDA equivalent)
- 503A/503B registered pharmacy only
Your Protocol Is Built Around Your Biology
Some patients reach optimal levels on a standardized estradiol patch and micronized progesterone capsule. Others need a compounded cream with a specific E2/P4/T ratio that no commercial product provides. Neither path is a fallback. Both are precision medicine when matched to the right patient.
Your provider selects the formulation based on your lab results, your symptom response, and your body’s tolerances. Not on a flowchart.
Discuss Your ProtocolThe Tactus Path to BHRT
Estradiol, progesterone, testosterone, SHBG, FSH, and LH. Your starting point determines your protocol, not a generic template.
Your provider selects the bioidentical formulation, whether standardized or compounded, that best matches your physiology.
Follow-up labs at 8 to 12 weeks guide dosing refinement. Your protocol evolves with your biology, not on a fixed schedule.
The Two Decisions That Change the Risk Profile
How you deliver estrogen and which progestogen you use are the most consequential prescribing decisions in bioidentical HRT safety.
Sources: Canonico et al., ESTHER Study (2007); Fournier et al., E3N Cohort (2008); NAMS Position Statement (2022).
Low-Dose Testosterone for Women: Why It Matters
Women produce testosterone in the ovaries and adrenal glands. Levels decline with age and drop further with surgical menopause. When testosterone falls, it shows up as fatigue, low libido, cognitive fog, and muscle loss, symptoms that estrogen alone often does not fix.
No FDA-approved testosterone product exists for women in the US. We use precision-dosed compounded creams to safely restore libido and cognitive drive without androgenic side effects. The dose is 10 to 20 times lower than male TRT, calibrated to physiologic female levels confirmed by lab work.
Signs Low Testosterone May Be Part of Your Picture
Many women who are already on estrogen therapy and still feel “not quite right” have low testosterone as the missing variable. When your panel shows suboptimal levels alongside symptoms, a small dose can make a significant difference in how you feel day to day.
- Persistent low libido despite estrogen
- Cognitive fog not resolved by E2
- Muscle weakness and body composition changes
- Unexplained low motivation
- Fatigue despite adequate sleep
- Lab-confirmed low total or free testosterone
Bioidentical vs. Conventional: The Evidence
| Feature | Bioidentical (Tactus Default) | Conventional Synthetic |
|---|---|---|
| Molecular structure matches human hormones | ✓ | ✕ |
| VTE risk via transdermal route | No increase | Elevated (oral route) |
| Breast cancer signal (progestogen) | Lower (micronized P4) | Higher (MPA) |
| GABA receptor support for sleep & anxiety | ✓ | ✕ |
| Cardiovascular benefit preserved | ✓ | Partially negated by MPA |
| FDA-approved formulations available | ✓ | ✓ |
| Low-dose testosterone for women available | ✓ | ✕ |
Sources: ESTHER Study (2007), E3N Cohort (2008), NAMS 2022 Position Statement. Individual risk assessment required.
Dr. Ashar N.
Dr. Ashar holds a Doctor of Nursing Practice and two national board certifications, one in family practice and one in psychiatric mental health.
She founded Tactus Health to close the gap she watched her own family fall through: symptoms that were real, labs that came back normal, and no one willing to connect the two.
She is responsible for the protocols our medical team follows, and for the training of the clinicians who deliver them. Holding both certifications is why those protocols treat hormones, mood, sleep and metabolism as one system rather than five separate appointments.
Bioidentical Hormone Therapy FAQ
More precisely: specific bioidentical formulations have a more favorable risk profile than the specific synthetic formulations studied in the WHI. Transdermal estradiol carries no statistically significant increased VTE risk. Micronized progesterone carries a lower breast cancer signal than medroxyprogesterone acetate. The distinction between “bioidentical” and “conventional” matters, but the delivery route and progestogen choice matter equally. Your provider reviews your individual risk profile during your free consultation.
Both can be bioidentical. FDA-approved options are standardized, batch-tested, and widely available. Compounded formulations allow for precision dosing, combined hormones, and concentrations that standard products do not offer. Your provider selects based on your lab results and symptom response, not on a default preference for one over the other.
FDA-approved bioidentical hormones are often covered by insurance plans with a valid diagnosis. Estradiol patches (Climara, Vivelle-Dot) and micronized progesterone (Prometrium) have generic versions covered by most major plans. Compounded BHRT is generally cash-pay because insurance does not cover custom compounded medications. HSA and FSA accounts are accepted for all hormone therapy services at Tactus Health.
Women produce testosterone in the ovaries and adrenal glands, and levels decline with age and menopause. Low testosterone in women contributes to fatigue, low libido, cognitive fog, and muscle loss, symptoms that estrogen alone often does not fully resolve. Because no FDA-approved testosterone product exists for women in the US, we use precision-dosed compounded creams to safely restore these benefits. Dosing is calibrated to physiologic female levels confirmed by lab work.
Yes. Oral and transdermal BHRT consultations, labs, and ongoing management are available via telehealth. Your prescription is sent to a pharmacy near you or shipped from a licensed compounding pharmacy. Labs are completed at any Quest Diagnostics or Labcorp location.
Bioidentical hormone replacement therapy is a prescription medical treatment requiring licensed clinical oversight. Compounded hormones are not FDA-approved as finished drug products. Women with active estrogen-receptor-positive breast or uterine cancer should discuss risks and alternatives with their oncologist before considering BHRT. Undiagnosed vaginal bleeding requires evaluation prior to initiating any hormone therapy. Individual results vary. This page is for informational purposes and does not constitute medical advice. Questions: [email protected] | (678) 892-9230 | 1400 Buford Hwy NE Suite K 2, Sugar Hill, GA 30518.
Related Services
Bioidentical Hormone Therapy Across Georgia
Tactus Health provides bioidentical hormone therapy to women across Georgia, from our clinic in Sugar Hill to telehealth patients in Atlanta, Savannah, Augusta, Alpharetta, Marietta, Duluth, Cumming, and beyond. We work with both local retail pharmacies and licensed compounding pharmacies to ensure your treatment is accessible and affordable regardless of where you live.
In-person appointments are available in Sugar Hill, Gwinnett County. Telehealth consultations are available to all Georgia residents. Labs are drawn at Quest Diagnostics and Labcorp locations statewide.
Find Your Protocol.
Free consultation. Your provider will review your labs, symptoms, and history, then recommend the bioidentical formulation and delivery method that fits your biology.